文献速递甲状腺疾病

甲状腺峡部结节与癌的细胞学及分子评估

Cytologic and Molecular Assessment of Isthmus Thyroid Nodules and Carcinomas.
PubMed 文献 · Thyroid · 2024-11-11

本研究基于Afirma甲状腺结节数据库(n=177,227)的观察性队列,比较峡部与叶部结节的细胞学和分子差异,并分析583例甲状腺乳头状癌(PTC)的分子特征。结果显示峡部结节Bethesda V-VI类比例更高(8.2% vs 4.3%),BRAF p.V600E、ALK/NTRK/RET融合及SPOP变异频率更高,NRAS突变和PAX8::PPARγ融合频率更低;峡部浸润性滤泡亚型PTC(IF-PTC)更具BRAF样特征且ERK和FMT评分更高。结论提示峡部结节更易有恶性细胞学及高风险分子改变,但是否需要改变手术或管理策略尚需更多数据。

要点

  • 峡部结节Bethesda V-VI类比例约为叶部两倍(8.2% vs 4.3%)。
  • 峡部结节BRAF p.V600E频率为叶部两倍(21% vs 10.6%)。
  • 峡部IF-PTC较叶部IF-PTC更具BRAF样特征且ERK和FMT评分更高。

核心结论

  • 峡部结节较叶部结节更易出现恶性细胞学及高风险分子改变。
  • 峡部IF-PTC与叶部IF-PTC在分子特征上存在差异。
  • 尚需更多数据明确峡部甲状腺癌是否需改变手术方式及分子数据是否应影响其管理与监测。

研究设计与样本

  • 观察性队列研究,评估Afirma甲状腺结节数据库(n=177,227)中峡部与叶部结节的细胞学和分子差异。
  • 对来自Afirma发现队列及整合内分泌外科社区实践管理的甲状腺癌患者 histopathology 报告(n=583)进行分析,其中PTC 389例、IF-PTC 194例。
  • 进行全基因组差异表达分析以解析转录组差异。

主要发现

  • Afirma数据库中识别出峡部结节8527个(4.8%)。
  • 峡部结节Bethesda V-VI类比例为8.2%,叶部为4.3%(p<0.0001)。
  • 峡部结节BRAF p.V600E频率为21%,叶部为10.6%(p<0.0001)。
  • 峡部结节ALK/NTRK/RET融合频率为4.6%,叶部为2.5%(p<0.0001);SPOP变异频率为1.5%,叶部为0.8%(p<0.0001)。
  • 峡部结节NRAS突变频率为7.8%,叶部为13.2%(p<0.0001);PAX8::PPARγ融合频率为1.1%,叶部为2.3%(p<0.0001)。

关键数值与推荐

  • 转录组分析显示峡部结节BRAF样评分、ERK活性、滤泡间质转化(FMT)评分更高,炎症活性评分更低。
  • 通路富集分析显示峡部肿瘤中下调基因富集于免疫应答调控。
  • 峡部IF-PTC(n=13)较叶部IF-PTC(n=181)更具BRAF样特征且ERK和FMT评分更高(所有p<0.01)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 需要更多数据以明确峡部甲状腺癌相对叶部癌是否需要改变手术治疗。
  • 需要更多数据以明确该分子数据是否应影响峡部甲状腺癌的管理和监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background: Isthmic thyroid nodules are more likely to be malignant and isthmic differentiated thyroid cancer demonstrates less favorable behavior compared with lobar locations. The goal of this study was to assess molecular differences of thyroid nodules and carcinomas from the isthmus relative to the lobes. Methods: The Afirma thyroid nodule database (n = 177,227) was assessed for cytologic and molecular differences between isthmus and lobar nodules in this observational cohort study. Genome-wide differential expression analysis was conducted to decipher transcriptomic differences. Histopathology reports (n = 583) of papillary thyroid cancer (PTC) (n = 389) and infiltrative follicular subtype of PTC (IF-PTC) (n = 194) from Afirma discovery cohorts and from thyroid cancer patients managed at an integrative endocrine surgery community care practice were analyzed for molecular differences between isthmic and lobar cancers. Results: In the Afirma database, 8527 (4.8%) isthmus nodules were identified. Bethesda V-VI nodules were almost twice as prevalent from the isthmus as compared with the lobes (8.2% vs. 4.3%, p < 0.0001). Isthmus nodules had twice the frequency of BRAFp.V600E (21% vs. 10.6%, p < 0.0001), an increased frequency of ALK/NTRK/RET fusions (4.6% vs. 2.5%, p < 0.0001) and SPOP variants (1.5% vs. 0.8%, p < 0.0001), and a lower frequency of NRAS mutations (7.8% vs. 13.2%, p < 0.0001), and PAX8::PPARy fusions (1.1% vs. 2.3%, p < 0.0001) than lobar nodules. Transcriptome analysis of molecular signatures and genome-wide analysis showed that isthmus nodules have higher BRAF-like scores, ERK activity, follicular mesenchymal transition scores (FMT), and lower inflammation activity scores. Pathway enrichment analysis revealed genes downregulated in isthmus tumors are enriched in immune response regulation. IF-PTC from the isthmus (n = 13) were more BRAF-like and had increased ERK and FMT scores compared with those from the lobes (n = 181) (p < 0.01 for all). Conclusions: These data suggest isthmic nodules are more likely to have malignant cytology and increased rates of higher risk molecular alterations compared with lobar nodules. IF-PTC from the isthmus is molecularly different compared with IF-PTC from the lobes. More data are needed to know if a change in surgical therapy is warranted in isthmic thyroid cancers relative to lobar cancers and if this molecular data should influence isthmic thyroid cancer management and monitoring.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Jasim S, Golding A, Bimston D, et al. Cytologic and Molecular Assessment of Isthmus Thyroid Nodules and Carcinomas. Thyroid. 2024. PMID: 39527399. doi:10.1089/thy.2024.0254

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。